NVS logo

NVS
Novartis AG

6,845
Mkt Cap
$268.3B
Volume
1.09M
52W High
$170.46
52W Low
$104.93
PE Ratio
20.76
NVS Fundamentals
Price
$146.57
Prev Close
$147.85
Open
$148.14
50D MA
$154.15
Beta
0.29
Avg. Volume
1.5M
EPS (Annual)
$7.25
P/B
7.26
Rev/Employee
$728,224.22
$293,740.89
Loading...
Loading...
News
all
press releases
Alnylam Q1 Earnings Beat Estimates, Amvuttra Sales Drive Y/Y Growth
ALNY beats Q1 earnings and revenue estimates as Amvuttra sales surge 187%, driving 96% revenue growth and offsetting declines in collaborator revenue and Onpattro sales.
Zacks·1d ago
News Placeholder
More News
News Placeholder
November 20th Options Now Available For Novartis (NVS)
Investors in Novartis (Symbol: NVS) saw new options become available today, for the November 20th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 203 days until expiration the newly available contracts rep...
Nasdaq News: Markets·1d ago
News Placeholder
Novartis AG $NVS Shares Acquired by US Bancorp DE
US Bancorp DE lifted its position in shares of Novartis AG (NYSE:NVS - Free Report) by 5.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities...
MarketBeat·1d ago
News Placeholder
Erste Group Bank Raises Earnings Estimates for Novartis
Novartis AG (NYSE:NVS - Free Report) - Analysts at Erste Group Bank increased their FY2027 earnings per share (EPS) estimates for shares of Novartis in a research report issued on Monday, April 27th. Erste Group Bank analyst H. Engel now anticipates that the company will post earnings per share of...
MarketBeat·2d ago
News Placeholder
Novartis AG $NVS Shares Sold by UBS Group AG
UBS Group AG trimmed its stake in shares of Novartis AG (NYSE:NVS - Free Report) by 15.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission...
MarketBeat·2d ago
News Placeholder
Erste Group Bank Weighs in on Novartis FY2026 Earnings
Novartis AG (NYSE:NVS - Free Report) - Stock analysts at Erste Group Bank cut their FY2026 EPS estimates for Novartis in a report released on Monday, April 27th. Erste Group Bank analyst H. Engel now...
MarketBeat·3d ago
News Placeholder
Novartis Q1 Earnings Call Highlights
Novartis (NYSE:NVS) executives said the company delivered a strong start to the year in the first quarter of 2026, led by fast growth across its priority brands and launches, while results reflected...
MarketBeat·4d ago
News Placeholder
Novartis CEO warns of reality of Trump's drug pricing policy
Novartis' CEO warned Tuesday that the U.S. drug pricing policy under President Donald Trump poses a very difficult situation and the reality will soon catch up with both drugmakers and patients...
CNBC Television-YouTube·4d ago
News Placeholder
LLY Expands Oncology Pipeline With $2.3B Ajax Therapeutics Acquisition
Lilly is set to acquire Ajax Therapeutics for up to $2.3B, gaining a novel JAK2 inhibitor as it ramps up oncology bets and targets unmet needs in MPN treatment.
Zacks·4d ago
News Placeholder
INCY Q1 Earnings and Revenues Beat Estimates on Higher Product Sales
Incyte tops Q1 estimates with $1.27 billion in revenues and strong earnings, fueled by Jakafi growth and rising Opzelura demand.
Zacks·4d ago
<
1
2
...
>

Latest NVS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.